Alpha Teknova, Inc.
HealthcareNASDAQ:TKNO · NASDAQ Global Market
-$0.20 today
Vol 0.15M · Avg 0.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-25.1%
avg -22.3%
ROIC
-17.3%
avg -15.0%
ROA
-16.7%
avg -14.5%
Analysis
ROA is currently the strongest return metric at -16.7% versus its period average of -14.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Stephen Gunstream | President, Chief Executive Officer & Director | $937,786.00 | — | 46 | $269,497.00 | 0.50% |
Matthew C. Lowell | Chief Financial Officer | $599,231.00 | — | 55 | $168,376.00 | 0.31% |
Damon A. Terrill | General Counsel, Chief Compliance Officer & Secretary | $578,923.00 | — | 55 | $148,000.00 | 0.28% |
Jennifer Henry | Senior Vice President of Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$143,417.20
Sells
1
$40,512.00
Net Sentiment
+$102,905.20
Net buying
Most Active
Gunstream Stephen
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | Gunstream Stephen Direct | Buy | 26.0K | $2.15 | $55,801.20 | |
| Mar 6, 2026 | Lowell Matthew Direct | Buy | 40.0K | $2.19 | $87,616.00 | |
| Jun 27, 2025 | DEMSKI MARTHA J Direct | Sell | 8.0K | $5.06 | $40,512.00 |
Analysis
Insiders reported 2 buys worth $143,417.20 and 1 sells worth $40,512.00 over the last 12 months. That adds up to net buying of $102,905.20. Gunstream Stephen was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +5.4% | +15.2% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +5.4% over three years. Forward estimates point to Revenue at +15.2% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$679.20M
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
$600.84M
Canopy Growth Corporation
NASDAQ:CGC
$425.84M
NeoGenomics, Inc.
NASDAQ:NEO
$290.37M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$211.55M
Aurora Cannabis Inc.
NASDAQ:ACB
$172.40M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$151.72M
CVRx, Inc.
NASDAQ:CVRX
$133.48M
Exagen Inc.
NASDAQ:XGN
$112.83M
Immutep Limited
NASDAQ:IMMP
$53.60M
Who manages TKNO?
Alpha Teknova, Inc. (TKNO) lists 4 active executives. The top listed executive is Damon A. Terrill, General Counsel, Chief Compliance Officer & Secretary.
Are TKNO insiders buying or selling?
Recent insider activity shows net buying of $51.35M.
Explore More
Continue the stock analysis
Jump to another research area for this company.